Associated Papers
Metastatic breast cancer in primary lung cancer with compound EGFR mutations: A case report.
Yang T et al.
Oncology Letters, 2026
Diagnostic accuracy of next-generation sequencing (NGS) for identifying actionable mutations in advanced non-small cell lung cancer: Systematic Review and Meta-Analysis.
Téllez Castillo N et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026
Quantum mechanics as a tool to decipher the mutational landscape of human disease.
Zavitsanou EI et al.
Progress in Biophysics and Molecular Biology, 2026
Sortilin exhibits tumor suppressor-like activity by limiting EGFR transduction function.
Lapeyronnie E et al.
Oncogene, 2026
HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction.
Wu F et al.
Cancer Letters, 2026
IsoPS-DIA: Dual Functionality of Absolute Targeted Quantification and Global Proteome Profiling.
Chan HJ et al.
Analytical Chemistry, 2026
Elucidating the role of the T790M mutation in BLU-945 selectivity for mutant EGFR: structural and energetic insights.
Tariq A et al.
Journal of Computer-aided Molecular Design, 2026
Database of recurrent mutations, an unbiased web resource to browse recurrent mutations in cancers.
Chakroborty D et al.
Iscience, 2026
A multiplex, prime editing framework for identifying drug resistance variants at scale.
Abadie FMC et al.
Cell Genomics, 2026
Coexistence of a primary ALK-positive and MET14 exon skipping mutation double-fusion in one patient with NSCLC and response to crizotinib: A case report and literature review.
Xu K et al.
Medicine, 2026
Gene duplication is associated with gene diversification and potential neofunctionalization in lung cancer evolution.
Ashford P et al.
Genome Research, 2026
Prognostic impact and treatment options for EGFR-mutant non-small cell lung cancer with concurrent EGFR amplification.
Yin LX et al.
Lung Cancer (amsterdam, Netherlands), 2026
Upfront treatment with osimertinib in lung cancer patients with and without active brain metastases, and the role of ctDNA as a biomarker; a phase II clinical trial (the FIOL study).
Stensland EM et al.
Lung Cancer (amsterdam, Netherlands), 2026
TP53 Functional-Domain-Specific Mutations Define Distinct Clinical Outcomes in EGFR-Mutant Non-Small Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Kobayashi K
Journal of Clinical Medicine, 2026
A CRISPR/Cas9-regulated dual-ring topological allosteric probe for detection of the EGFR L858R resistance mutation in CTCs.
Wang C et al.
Analytical Methods : Advancing Methods and Applications, 2026
Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.
Rakaee M et al.
Jama Oncology, 2026
Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing.
Carnero-Gregorio M et al.
Genes, 2026
Metastatic colorectal adenocarcinoma with APC and EGFR L858R co-mutations: a case report.
Cavalheiro VJ et al.
The Oncologist, 2026
Comparative analysis of ctDNA monitoring strategies in advanced NSCLC with MET exon 14 skipping mutations treated with ensartinib.
Zhou M et al.
Npj Precision Oncology, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer.
Azuma K et al.
Cancer Treatment and Research Communications, 2026
Co-occurrence of lung adenocarcinoma with rapidly progressive dementia and multiple cerebral microbleeds: a case report.
Yan J et al.
Journal of Medical Case Reports, 2026
Spatial multi-omics unveils the monoclonal origin, neuroendocrine plasticity, and microenvironment niches in combined small cell lung cancer.
Wang Z et al.
Biorxiv : the Preprint Server for Biology, 2026
Successful treatment with erlotinib plus ramucirumab in a patient with non-small-cell lung cancer harboring EGFR exon 20 insertion mutation.
Nakashima K et al.
Anti-cancer Drugs, 2026
Using the Reactome Graph Database to generate pathway fingerprints for cancer-related genes, and using the fingerprints to gain insights into cancer, comorbidity, and cancer gene networks.
Iengar P et al.
Computational Biology and Chemistry, 2026
Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series.
Li JJ et al.
Pathology, 2026
The role of APOBEC in early-stage epidermal growth factor receptor-mutant non-small cell lung cancer.
Jung HA et al.
Lung Cancer (amsterdam, Netherlands), 2026
Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.
Saito Y et al.
Nature Medicine, 2026
Individualized management strategies for advanced non-small cell lung cancer with EGFR exon 19 deletion and L861Q compound mutations based on circulating tumor DNA monitoring: A case report.
Zhu X et al.
Oncology Letters, 2026
Integrating evidence from protein domains to identify cancer driver mutations.
Ostroverkhova D et al.
Protein Science : a Publication of the Protein Society, 2026
Targeted Protein Degradation Strategies for Lung Cancers: Focusing on Epidermal Growth Factor Receptor.
Hou M et al.
Chemistry & Biodiversity, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?
Abdayem P et al.
Drugs, 2026
TP53 co-mutations are associated with elevated PD-L1 expression and high tumor mutational burden in non-small cell lung cancer: insights from comprehensive genomic profiling.
Yang Y et al.
Translational Lung Cancer Research, 2026
The efficacy and predictive factors of first-line immune checkpoint inhibitors for advanced non-small cell lung cancer with driver or non-driver gene alterations: a retrospective cohort study.
He Q et al.
Journal of Thoracic Disease, 2026
Radiological, Radiomics, and Metastatic Patterns Associated with Targetable Oncogenic Drivers on CT-Scan of Newly Diagnosed NSCLC Patients: A Comprehensive Radiogenomics Review.
Phan L et al.
Cancers, 2026
Effects of N361 Glycosylation on Epidermal Growth Factor Receptor Biological Function.
Lam D et al.
Cancers, 2026
Genomic landscape of stage 0-IA lung adenocarcinoma identified by on-site reflex targeted NGS.
Ilié M et al.
Lung Cancer (amsterdam, Netherlands), 2026
Integrative clinico-molecular analysis reveals actionable subtypes and biomarkers in lung adenocarcinoma.
Shang J et al.
Cell Discovery, 2026
Magnolol suppresses TKI-resistant EGFR-mutant lung cancer by inhibiting EGFR and AXL-cMyc.
Chen CC et al.
European Journal of Pharmacology, 2026
Circulating Tumor Cell-based Molecular Responses Stratify EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Cancer.
Lee S et al.
Cancer Research and Treatment, 2026
Circ_0001839 modulates the oncogenic MYCL rs1038259890 (p.G83S) mutation to promote B[a]P-induced malignant transformation in 16HBE cells.
Chen X et al.
Journal of Hazardous Materials, 2026
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis.
Bronte G et al.
Journal of Clinical Medicine, 2026